Rekombinanter Humaner B- und T-Lymphozyten-Attenuator/BTLA/CD272 (C-mFc), geliefert von Elabscience mit vom Kooperationspartner bereitgestellten technischen Spezifikationen.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human B- and T-Lymphocyte Attenuator/BTLA/CD272 (C-mFc) is a research-use recombinant protein from Elabscience preparation representing BTLA supplied as Lyophilized. Review the expression, purity, formulation and storage specifications below before selecting it for an assay or functional workflow.
Fully tested in-house by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | Bioaktivität | Bindung | Zellbasiert | In Vivo | ELISA-Capture |
|---|---|---|---|---|---|
| Human |
This product is manufactured by Elabscience and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
BTLA (B and T lymphocyte associated), commonly called B- and T-lymphocyte attenuator or CD272, is an inhibitory lymphocyte receptor studied in antigen-receptor signalling and adaptive immune regulation.
Biological function: BTLA is a cell-surface inhibitory receptor that attenuates antigen-receptor signalling through the phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. Reviewed human evidence also supports cis and trans interactions with TNFRSF14/HVEM, placing BTLA in regulatory circuits that tune lymphocyte activation and resting state.
